Limits...
Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.

Takahashi M, Hayashida T, Okazaki H, Miyao K, Jinno H, Kitagawa Y - Cancer Sci. (2014)

Bottom Line: To determine if BTG2 expression modifies tamoxifen efficacy, a cohort of 60 patients treated with adjuvant tamoxifen monotherapy was analyzed.We found that increased BTG2 expression showed better clinical survival and was the only independent prognostic factor for disease-free survival (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; P = 0.029).These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Association of B-cell translocation gene 2 (BTG2) expression with disease-free survival (DFS) in patients who received tamoxifen alone as adjuvant therapy. A cohort of 60 breast cancer tumors compiled from the GEO datasets GDS80718 was dichotomized into groups expressing either high or low levels of BTG2 and Kaplan–Meier curves were constructed for the probability of DFS in each group (log-rank test, P = 0.029).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317889&req=5

fig01: Association of B-cell translocation gene 2 (BTG2) expression with disease-free survival (DFS) in patients who received tamoxifen alone as adjuvant therapy. A cohort of 60 breast cancer tumors compiled from the GEO datasets GDS80718 was dichotomized into groups expressing either high or low levels of BTG2 and Kaplan–Meier curves were constructed for the probability of DFS in each group (log-rank test, P = 0.029).

Mentions: A previous expression analysis study in human breast carcinoma showed a loss of nuclear expression of BTG2 protein in 46% of tumors.6 Analysis of the Oncomine data set also revealed a strong correlation between decreased BTG2 expression and recurrence in patients undergoing tamoxifen treatment.11 To further validate the ability of BTG2 loss to predict the response to tamoxifen monotherapy, we analyzed gene expression data generated from a collection of laser-microdissected breast cancer samples (n = 60) from subjects who received tamoxifen alone as adjuvant systemic therapy (GEO database accession no. GDS807). According to the original study, patient inclusion criteria was defined as women diagnosed at the Massachusetts General Hospital between 1987 and 2000 with hormone receptor-positive breast cancer, treated with standard breast surgery, followed by 5 years of systemic adjuvant tamoxifen. No patient who received chemotherapy prior to recurrence was allowed.18 The list of patient and tumor characteristics (tumor size, histological grade, lymph node status, age and status of ER, PR and HER2) is available in a previous publication.18 Statistical analyses revealed that higher histological grade (P = 0.007) and lymph node negativity (P = 0.043) were significantly associated with BTG2 suppression (Table1). We also conducted stepwise variable selection of the Cox proportional hazards regression model to identify clinical variables and BTG2 expression that were significant predictors of DFS. The results identified increased BTG2 expression as the only independent prognostic factor for DFS (hazard ratio, 0.691; 95% confidence interval, 0.495–0.963; P = 0.029). The DFS curve was drawn using Kaplan–Meier estimates and compared using log-rank tests. It revealed that patients with tumors displaying increased BTG2 expression showed good clinical outcomes with a statistically significant difference (Fig.1).


Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.

Takahashi M, Hayashida T, Okazaki H, Miyao K, Jinno H, Kitagawa Y - Cancer Sci. (2014)

Association of B-cell translocation gene 2 (BTG2) expression with disease-free survival (DFS) in patients who received tamoxifen alone as adjuvant therapy. A cohort of 60 breast cancer tumors compiled from the GEO datasets GDS80718 was dichotomized into groups expressing either high or low levels of BTG2 and Kaplan–Meier curves were constructed for the probability of DFS in each group (log-rank test, P = 0.029).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317889&req=5

fig01: Association of B-cell translocation gene 2 (BTG2) expression with disease-free survival (DFS) in patients who received tamoxifen alone as adjuvant therapy. A cohort of 60 breast cancer tumors compiled from the GEO datasets GDS80718 was dichotomized into groups expressing either high or low levels of BTG2 and Kaplan–Meier curves were constructed for the probability of DFS in each group (log-rank test, P = 0.029).
Mentions: A previous expression analysis study in human breast carcinoma showed a loss of nuclear expression of BTG2 protein in 46% of tumors.6 Analysis of the Oncomine data set also revealed a strong correlation between decreased BTG2 expression and recurrence in patients undergoing tamoxifen treatment.11 To further validate the ability of BTG2 loss to predict the response to tamoxifen monotherapy, we analyzed gene expression data generated from a collection of laser-microdissected breast cancer samples (n = 60) from subjects who received tamoxifen alone as adjuvant systemic therapy (GEO database accession no. GDS807). According to the original study, patient inclusion criteria was defined as women diagnosed at the Massachusetts General Hospital between 1987 and 2000 with hormone receptor-positive breast cancer, treated with standard breast surgery, followed by 5 years of systemic adjuvant tamoxifen. No patient who received chemotherapy prior to recurrence was allowed.18 The list of patient and tumor characteristics (tumor size, histological grade, lymph node status, age and status of ER, PR and HER2) is available in a previous publication.18 Statistical analyses revealed that higher histological grade (P = 0.007) and lymph node negativity (P = 0.043) were significantly associated with BTG2 suppression (Table1). We also conducted stepwise variable selection of the Cox proportional hazards regression model to identify clinical variables and BTG2 expression that were significant predictors of DFS. The results identified increased BTG2 expression as the only independent prognostic factor for DFS (hazard ratio, 0.691; 95% confidence interval, 0.495–0.963; P = 0.029). The DFS curve was drawn using Kaplan–Meier estimates and compared using log-rank tests. It revealed that patients with tumors displaying increased BTG2 expression showed good clinical outcomes with a statistically significant difference (Fig.1).

Bottom Line: To determine if BTG2 expression modifies tamoxifen efficacy, a cohort of 60 patients treated with adjuvant tamoxifen monotherapy was analyzed.We found that increased BTG2 expression showed better clinical survival and was the only independent prognostic factor for disease-free survival (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; P = 0.029).These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus